Sign Up
OverviewAPI
A study reveals that many cancer drugs approved through accelerated pathways lack significant benefits after five years. Ribometrix presents promising data on RNA-targeting platforms for cancer treatment, aiming to file an IND in 2025. Medtronic's SMART trial demonstrates the superiority of Evolut TAVR over Sapien in treating severe aortic stenosis, emphasizing tailored valve selection.

Ask a question